Clinical data
ATC code L02BG05 (WHO)
Pharmacokinetic data
Bioavailability Very high
Metabolism Hepatic
Biological half-life 8 hours
CAS Number 118949-22-7 N
PubChem (CID) 6918191
ChemSpider 5293402 YesY
KEGG D03786 YesY
Chemical and physical data
Formula C16H13ClN6
Molar mass 324.768 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Vorozole is an imidazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.

It is selective.[1]


  1. Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Res. Treat. 49. Suppl 1: S59–65; discussion S73–7. doi:10.1023/a:1006052923468. PMID 9797019.

This article is issued from Wikipedia - version of the 6/12/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.